Abstract:Small molecule kinase inhibitors are one of the fastest growing classes of drugs, which are approved by the US Food and Drug Administration (FDA) for cancer and non-cancer indications. As of September 2023, there were over 70 FDA-approved small molecule kinase inhibitors on the market, 42 of which were approved in the past five years (2018-2023). This minireview discusses recent advances in our understanding of the pharmacology, metabolism, and toxicity profiles of recently approved kinase inhibitors with a central focus on tyrosine kinase inhibitors (TKIs). In this minireview we discuss the most common therapeutic indications and molecular target(s) of kinase inhibitors FDA-approved 2018-2023. We also describe unique aspects of the metabolism, bioactivation, and drug-drug interaction (DDI) potential of kinase inhibitors; discuss drug toxicity concerns related to kinase inhibitors, such as drug-induced liver injury; and highlight clinical outcomes and challenges relevant to TKI therapy. Case examples are provided for common TKI targets, metabolism pathways, DDI potential, and risks for serious adverse drug reactions. The minireview concludes with a discussion of perspectives on future research to optimize TKI therapy to maximize efficacy and minimize drug toxicity. <b>Significance Statement</b> This minireview highlights important aspects of the clinical pharmacology and toxicology of small molecule kinase inhibitors FDA-approved 2018-2023. We describe key advances in the therapeutic indications and molecular targets of tyrosine kinase inhibitors (TKIs). The major metabolism pathways and toxicity profiles of recently approved TKIs are discussed. Clinically relevant case examples are provided that demonstrate the risk for hepatotoxic drug interactions involving TKIs and co-administered drugs.

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (part I): Kinase Inhibitors.

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

Targeting cancer with small molecule kinase inhibitors

Current Status of Research and Development of New Tyrosine Kinase Inhibitors

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Kinase-targeted cancer therapies: progress, challenges and future directions

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Small Molecule Inhibitors Targeting the Cancers

Small Molecules Targeting Phosphoinositide 3-Kinases

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

Trends in kinase drug discovery: targets, indications and inhibitor design

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Targeting Protein Kinases Benefits Cancer Immunotherapy.

Small Molecule Modulators Targeting Protein Kinase CK1 and CK2

Perturbation of biological processes with small molecule kinase inhibitors

An Overview of Kinase Downregulators and Recent Advances in Discovery Approaches.